Haemonetics (HAE) Tops Q3 EPS by 4c, Revenues Miss; Offers FY19 EPS Mid-Point Guidance Below Consensus

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $247 million versus the consensus estimate of $250.13 million.

Chris Simon, Haemonetics’ CEO, stated: “Our third quarter performance met our expectations
and reinforces that our strategy is working. Our Plasma and Hospital launches are propelling us
forward while our Complexity Reduction Initiative is improving profitability and freeing up
resources needed for investments. We are confident that our value drivers will continue to
strengthen Haemonetics’ growth trajectory.”

PDF LINK

GUIDANCE:

Haemonetics sees FY2019 EPS of $2.25-$2.35, versus the consensus of $2.33.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Citi upgrades Haemonetics to Buy, raises price target to $123
• Amneal gets FDA approval for lanreotide injection, launches immediately
• Wells Fargo cuts Netflix rating on engagement risk, weak slate